AstraZeneca has taken another step toward the completion of its new headquarters and R&D hub in Cambridge, U.K.
Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials.
It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses…
Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.
The FDA granted Allergan marketing authorization for its intranasal tear stimulator, which temporarily increases tear production in adult patients.
Novartis will play a bigger role in the marketing of Amgen's migraine drug erenumab, and analysts say the move may reflect reduced sales expectations.
Circassia CEO Steve Harris has defended the running of the company’s allergy trials, stating nothing could have been done better.
After raising $31 million just last year, California-based clinical research company Science 37 has now served up a Series C round worth $29 million.
Two Pore Guys closed a $24.5 million Series A round, which will boost the manufacturing of the company’s handheld testing system.
Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets.
It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the…